NEWS
12. July 2010
>RELDATA Named Tech Awards Circle Winner / Unified Block and File Storage Solutions Provider Selected ...
18. June 2010
>RELDATA Selected as AlwaysOn East Top 100 Winner for Cloud and Infrastructure Technology Unified Storage ...
7. June 2010
>On June 24, 2010, the 8th annual Grazia Equity Business Plan Competition was hosted at ...
5. June 2010
>immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced ...
2. June 2010
>Online-Brillenhändler Mister Spex zählt zu "Red Herring 100 Europe" Unternehmen Red Herring Europe Award ...
2. June 2010
>immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 ...
16. February 2010
>immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine ...
4. February 2010
>XConnect revenue doubled in 2009 XConnect, the leader in next-generation interconnection and carrier ENUM-registry ...
1. February 2010
>Online-Brillenhändler Mister Spex hat 2009 Brillen und Kontaktlinsen für rund 4,5 Millionen Euro verkauft – ...
26. January 2010
>RELDATA UNIFIED STORAGE NAMED ONE OF “100 COOLEST CLOUD COMPUTING PRODUCTS” BY EVERYTHING CHANNEL’S CRN ...
20. January 2010
>RELDATA (www.reldata.com), a provider of software-centric unified storage solutions, announced today its new RELDATA Partner ...
14. January 2010
>HORIZONT und Statista starten Portal HORIZONTstats.de Premium-Initiative für Paid Content Auf HORIZONTstats.de gibt es ...
9. December 2009
>First Chip Supplier to Offer 4x4 MIMO Wi-Fi Devices Will Play Active Role in One ...
2. December 2009
>Conergy Solar Factory in Frankfurt (Oder): Three Years "Quality Made in Germany" Ramp ...
20. November 2009
>Investoren-Einstieg unterstützt weitere Wachstumsstrategie Der Stuttgarter Finanzinvestor Grazia Equity ist beim After Sales Dienstleister ...
16. November 2009
>Allzu viele Partner bei der Finanzierung können das Wachstum eines jungen Unternehmens stören. Es kommt ...
22. October 2009
>COPRO will sich mit allen Projekten in der virtuellen Welt Twinity präsentieren. Als erstes ...
19. October 2009
>Mit Mister Spex bringt Dirk Graber den Durchblick zurück. Wir haben ihn zu seiner Arbeit ...
5. October 2009
>Statistik-Portal startet heute sein Premium-Angebot, das für 29,90 Euro pro Monat die Verwendung exklusiver Daten ...
1. October 2009
>"Gründerszene ist sehr unterentwickelt" Von Claus G. Schmalholz Lothar Späth, zuletzt Vorsitzender der ...
29. September 2009
>immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer ...
22. September 2009
>RELDATA Introduces Next Generation 9240i Unified Storage System Powered by Enhanced RELvos 2.4 Virtualization OS ...
16. September 2009
>Venture capital firms Venrock Associates, Accel Partners, Grazia Equity and Crescent Point Group all participated ...
9. September 2009
>Nanosolar Completes Panel Factory, Commences Serial Production Today Nanosolar demonstrated the completion of its ...
9. September 2009
>Nanosolar Unveils Nanosolar Utility Panel™ Technology In conjunction with today's inauguration of our panel-assembly ...
9. September 2009
>NREL Certifies 16.4% Nanosolar Foil Efficiency It was May 2006 when we last released ...
10. August 2009
>immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition ...
7. August 2009
>How creativity is helping the German capital cope with economic crisis. BERLIN — The ...
27. July 2009
>Portal will Informationen für Marketingentscheider bündeln Mit einem neuen Seitenkonzept will das Statistik-Portal „Statista“ ...
21. July 2009
>RELDATA Named a CRN Emerging Technology Vendor RELDATA's unified storage solutions provide channel partners ...
7. July 2009
>Ehemaliger Ministerpräsident arbeitet für Venture Capital-Geber: Lothar Späth berät Grazia Equity Prof. Dr. h.c. ...
7. July 2009
>Metaversum GmbH, developer of Twinity, the world’s first mirror world – a virtual world made ...
3. July 2009
>Grazia Equity Award für die beste Geschäftsidee an der HHL Von einer Charityplattform ...
30. June 2009
>Conergy sells solar portfolio with a capacity of 10.7 MWp ...
17. June 2009
>immatics biotechnologies significantly improves XPRESIDENT™ technology platform. immatics biotechnologies today announced the completion of ...
10. June 2009
>Australia: Planning Approval for 282 Wind Turbines EPURON reaches key milestone for the largest ...
8. June 2009
>Conergy Deutschland GmbH sells the Heimpersdorf megawatt solar park to investor Conergy Deutschland GmbH ...
5. June 2009
>Die zweite Auflage des Buches "IT-Governance in der Praxis" von den Autoren Andreas Rüter (Grazia ...
29. May 2009
>moviepilot.de: Führender personalisierbarer Entertainmentguide für Kino, DVD und TV schließt zweite Finanzierungsrunde ab Berlin, 29.05.2009 ...
19. May 2009
>Solarstrom von Conergy reduziert Kosten für Wasserversorgung in Kalifornien • 1,6 MWp Solarpark im ...
14. May 2009
>Statista startet Geschäftskunden-Angebot Statistik-Portal bietet umfassende Markenreports und kostengünstige Online-Umfragen Ausführliche Analysen zu ...
8. May 2009
>Solar energy from the region, for the region: Conergy Deutschland inaugurates a megawatt class thin-film ...
28. April 2009
>XCONNECT NAMES RICHARD SHOCKEY, ENUM PIONEER AND IP COMMUNICATIONS EXPERT, TO ADVISORY BOARD Appointment ...
27. April 2009
>RELDATA EXPANDS ITS SALES ORGANIZATION Industry Veteran Peter Cmaylo joins RELDATA as VP Sales ...
22. April 2009
>XCONNECT EXPANDS GLOBAL ALLIANCE FEDERATION SERVICES Innovations Bring Communications Service Providers More NGN ...
20. April 2009
>Must-have-Accessoires: Hält die Brille mit der It-Bag Schritt? Das Mister Spex "Brillen-Mode-Barometer" analysiert ...
8. April 2009
>Metaversum and Twinity has been elected a Red Herring 100 Europe Winner 2009 With ...
24. March 2009
>OVERGENCE SESSION MANAGER LATEST VOIP-PEERABLE DEVICE CERTIFIED XCONNECT-READY Testing for ENUM Query Compatibility Streamlines ...
2. March 2009
>immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell ...
24. February 2009
>Quantenna Raises $15 Million in Series D Financing Round Quantenna Communications, Inc., a leader ...
24. February 2009
>RELDATA AND XYRATEX ENABLE HETEROGENEOUS STORAGE RELDATA 9240 and Xyratex F6412E RAID system certification ...
26. January 2009
>immatics wins 29th German Industry’s Innovation Award (Innovationspreis der deutschen Wirtschaft) Tuebingen, January 26, ...
26. January 2009
>The Growing Market for Solar Cells Printing is playing a key role in ...
24. January 2009
>VC Investing Drops For 2008, But Green Grows Venture capital investment shrank in 2008 ...
21. October 2008
>Metaversum Awarded Funding in Co-space™ program in Singapore Metaversum, developer and operator of ...
5. September 2008
>Wowereit Opens Virtual Berlin in Twinity Metaversum GmbH, developer and operator of the ...
2. March 2009
Phase II study with cancer vaccine
immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer. Clinical results for immatics‘ lead candidate expected by 2010.
immatics biotechnologies GmbH today announced having completed patient recruitment in a phase II trial with its cancer vaccine IMA901 in patients with advanced renal cell cancer (RCC). IMA901 is the most advanced of the innovative cancer vaccines developed by immatics.
A total of 68 metastatic RCC patients who had not responded to standard treatment, i.e. cytokine or tyrosine kinase inhibitor therapy, have been recruited. The primary objective of the trial is to measure the disease control rate after six months of treatment to assess if the vaccination is able to slow down or halt the tumor progression. The tumor assessments will be conducted via an independent central review process. Final results are expected for early 2010.
“We are very much looking forward to the results of this trial” said Dr Harpreet Singh, Chief Scientific Officer of immatics. "IMA901 is the first product candidate developed on the basis of our XPRESIDENT™ discovery platform. To our knowledge it is therefore the first cancer vaccine containing multiple peptides which have been confirmed to actually exist in human tumors."
Paul Higham, CEO of immatics, added: “The completion of recruitment in this our most advanced product is another important milestone for the company. It demonstrates continued good progress of our clinical development activities. Should we succeed in demonstrating good clinical effects, this trial may allow us to enter into earlier disease stages where there remains a very high unmet need for therapies that are both effective and well tolerated.”
About IMA901
IMA901 is an off-the-shelf peptide-based therapeutic vaccine specifically developed for the treatment of renal cell cancer (RCC). It consists of ten fully synthetic tumor-associated peptides (TUMAPs) representing tumor antigens relevant for renal cell cancer. These TUMAPs were identified based on the analysis of primary tumor tissue with immatics’ proprietary XPRESIDENT™ platform. Thus, they were confirmed to be naturally presented in human tumors. In addition, the peptides were chosen due to their ability to activate immune effector cells, i.e. cytotoxic T cells and T helper cells, against renal cell cancer.
About the study
The study is designed as an open label, randomized European multicenter phase II trial for patients with advanced renal cell cancer who did not respond to first-line cytokine therapy (interferon and/or interleukin-2) or tyrosine kinase inhibitor therapy (Sutent® or Nexavar®). The study examines the effect of a second-line systemic treatment with IMA901 plus GM-CSF as immunmodulator. It also investigates whether pre-treatment with a single low-dose application of cyclophosphamide (Endoxan®) can further improve the response to IMA901 and GM-CSF. The primary endpoint of the study is the disease control rate at six months after the first vaccination. The tumor assessments will be made via an independent central review process. The secondary endpoints include safety as well as various immune response and other biological parameters. The study has recruited 68 patients in ten European countries. Final results are expected for early 2010.
About immatics
immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Its lead products – IMA901 for the therapy of renal cell cancer and IMA910 for the treatment of colon cancer – are currently investigated in international phase II clinical studies. Since its foundation in 2000, immatics has raised more than €54 million (US$ 72million) in private equity in two financing rounds. The company has a headcount of more than 65 people and is based in Tuebingen and Munich, Germany.
For additional information please visit www.immatics.com or contact:
Katrin Eckert, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-565125-10
E-mail: media@immatics.com